These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1988 related items for PubMed ID: 29550085
1. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. Kerneis M, Gibson CM, Chi G, Mehran R, AlKhalfan F, Talib U, Pahlavani S, Mir M, Bode C, Halperin JL, Nafee T, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Fox KAA, Cohen M. JACC Cardiovasc Interv; 2018 Apr 09; 11(7):626-634. PubMed ID: 29550085 [Abstract] [Full Text] [Related]
2. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial. Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM. Circ Cardiovasc Interv; 2019 Nov 09; 12(11):e008160. PubMed ID: 31707805 [Abstract] [Full Text] [Related]
3. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM. Circ Cardiovasc Interv; 2019 Feb 09; 12(2):e007124. PubMed ID: 30704287 [Abstract] [Full Text] [Related]
4. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. Sherwood MW, Cyr DD, Jones WS, Becker RC, Berkowitz SD, Washam JB, Breithardt G, Fox KA, Halperin JL, Hankey GJ, Singer DE, Piccini JP, Nessel CC, Mahaffey KW, Patel MR. JACC Cardiovasc Interv; 2016 Aug 22; 9(16):1694-702. PubMed ID: 27539689 [Abstract] [Full Text] [Related]
5. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K. Am Heart J; 2015 Apr 22; 169(4):472-8.e5. PubMed ID: 25819853 [Abstract] [Full Text] [Related]
6. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. N Engl J Med; 2016 Dec 22; 375(25):2423-2434. PubMed ID: 27959713 [Abstract] [Full Text] [Related]
8. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH, RE-DUAL PCI Steering Committee and Investigators. Clin Cardiol; 2016 Oct 22; 39(10):555-564. PubMed ID: 27565018 [Abstract] [Full Text] [Related]